SCHEMBL4121624

SCHEMBL4121624

CCNC(=O)c1cnn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.45
PDE4B Q07343 2/20 0.45
PDE4C Q08493 2/20 0.45
PDE4D Q08499 2/20 0.45
HPGD P15428 2/20 0.42
CCNA2 P20248 2/20 0.42
CDK2 P24941 2/20 0.42
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 3/20 0.41
NPC1 O15118 2/20 0.41
POLB P06746 1/20 0.41
CNR1 P21554 2/20 0.41
CYP1A1 P04798 1/20 0.40
MAPT P10636 3/20 0.40
CNR2 P34972 1/20 0.40
HCAR2 Q8TDS4 1/20 0.40
KCNA3 P22001 1/20 0.39
KDM4E B2RXH2 2/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115722 0.89 CNR2 (0.42) HPGDCCNA2CDK2RAB9ASMN1; SMN2
SCHEMBL4129143 0.89 RAB9A (0.42) HPGDCCNA2CDK2RAB9ASMN1; SMN2
SCHEMBL1754487 0.86 TSHR (0.42) RAB9ASMN1; SMN2LMNANPC1POLB
SCHEMBL4118485 0.86 RAB9A (0.40) HPGDCCNA2CDK2RAB9ASMN1; SMN2
SCHEMBL4115065 0.85 RAB9A (0.52) HPGDCCNA2CDK2RAB9ASMN1; SMN2
SCHEMBL2083955 0.85 RAB9A (0.51) HPGDRAB9ASMN1; SMN2LMNANPC1
SCHEMBL4130891 0.84 SMN1; SMN2 (0.52) HPGDCCNA2CDK2SMN1; SMN2LMNA
SCHEMBL2083730 0.84 NPC1 (0.58) HPGDCCNA2CDK2RAB9ASMN1; SMN2
SCHEMBL1754002 0.83 LMNA (0.40) CCNA2CDK2RAB9ASMN1; SMN2LMNA
SCHEMBL2087398 0.83 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US claimed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US claimed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP claimed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO claimed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD PDE4A 2513/4885PDE4B 1938/4885PDE4C 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.